For patienter (n = 39) med recidiv inden for 180 dage efter kemo/ stråleterapi med cisplatin, var medianoverlevelsen i den gruppe, der fik topotecan + cisplatin 4, 6 mdr.
In patients (n=39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95% C. I.: